Practical challenges for precision medicine

Frederike H Petzschner,Frederike H. Petzschner

DOI: https://doi.org/10.1126/science.adm9218

IF: 56.9

2024-01-12

Science

Abstract:The prediction of individual treatment responses with machine learning faces hurdles

multidisciplinary sciences

What problem does this paper attempt to address?

Learning Personalized Treatment Decisions in Precision Medicine: Disentangling Treatment Assignment Bias in Counterfactual Outcome Prediction and Biomarker Identification

Michael Vollenweider,Manuel Schürch,Chiara Rohrer,Gabriele Gut,Michael Krauthammer,Andreas Wicki

2024-10-01

Abstract:Precision medicine offers the potential to tailor treatment decisions to individual patients, yet it faces significant challenges due to the complex biases in clinical observational data and the high-dimensional nature of biological data. This study models various types of treatment assignment biases using mutual information and investigates their impact on machine learning (ML) models for counterfactual prediction and biomarker identification. Unlike traditional counterfactual benchmarks that rely on fixed treatment policies, our work focuses on modeling different characteristics of the underlying observational treatment policy in distinct clinical settings. We validate our approach through experiments on toy datasets, semi-synthetic tumor cancer genome atlas (TCGA) data, and real-world biological outcomes from drug and CRISPR screens. By incorporating empirical biological mechanisms, we create a more realistic benchmark that reflects the complexities of real-world data. Our analysis reveals that different biases lead to varying model performances, with some biases, especially those unrelated to outcome mechanisms, having minimal effect on prediction accuracy. This highlights the crucial need to account for specific biases in clinical observational data in counterfactual ML model development, ultimately enhancing the personalization of treatment decisions in precision medicine.

Machine Learning,Information Theory,Quantitative Methods
Artificial Intelligence, Physiological Genomics, and Precision Medicine.

Anna Marie Williams,Yong Liu,Kevin R. Regner,Fabrice Jotterand,Pengyuan Liu,Mingyu Liang

DOI: https://doi.org/10.1152/physiolgenomics.00119.2017

2018-01-01

Physiological Genomics

Abstract:Big data are a major driver in the development of precision medicine. Efficient analysis methods are needed to transform big data into clinically-actionable knowledge. To accomplish this, many researchers are turning toward machine learning (ML), an approach of artificial intelligence (AI) that utilizes modern algorithms to give computers the ability to learn. Much of the effort to advance ML for precision medicine has been focused on the development and implementation of algorithms and the generation of ever larger quantities of genomic sequence data and electronic health records. However, relevance and accuracy of the data are as important as quantity of data in the advancement of ML for precision medicine. For common diseases, physiological genomic readouts in disease-applicable tissues may be an effective surrogate to measure the effect of genetic and environmental factors and their interactions that underlie disease development and progression. Disease-applicable tissue may be difficult to obtain, but there are important exceptions such as kidney needle biopsy specimens. As AI continues to advance, new analytical approaches, including those that go beyond data correlation, need to be developed and ethical issues of AI need to be addressed. Physiological genomic readouts in disease-relevant tissues, combined with advanced AI, can be a powerful approach for precision medicine for common diseases.
Precision psychiatry: predicting predictability

Edwin van Dellen

DOI: https://doi.org/10.1017/s0033291724000370

IF: 10.592

2024-03-20

Psychological Medicine

Abstract:Precision psychiatry is an emerging field that aims to provide individualized approaches to mental health care. An important strategy to achieve this precision is to reduce uncertainty about prognosis and treatment response. Multivariate analysis and machine learning are used to create outcome prediction models based on clinical data such as demographics, symptom assessments, genetic information, and brain imaging. While much emphasis has been placed on technical innovation, the complex and varied nature of mental health presents significant challenges to the successful implementation of these models. From this perspective, I review ten challenges in the field of precision psychiatry, including the need for studies on real-world populations and realistic clinical outcome definitions, and consideration of treatment-related factors such as placebo effects and non-adherence to prescriptions. Fairness, prospective validation in comparison to current practice and implementation studies of prediction models are other key issues that are currently understudied. A shift is proposed from retrospective studies based on linear and static concepts of disease towards prospective research that considers the importance of contextual factors and the dynamic and complex nature of mental health.

psychiatry,psychology, clinical
Problems, challenges and promises: perspectives on precision medicine

David J Duffy,David J. Duffy

DOI: https://doi.org/10.1093/bib/bbv060

IF: 9.5

2015-08-05

Briefings in Bioinformatics

Abstract:The 'precision medicine (systems medicine)' concept promises to achieve a shift to future healthcare systems with a more proactive and predictive approach to medicine, where the emphasis is on disease prevention rather than the treatment of symptoms. The individualization of treatment for each patient will be at the centre of this approach, with all of a patient's medical data being computationally integrated and accessible. Precision medicine is being rapidly embraced by biomedical researchers, pioneering clinicians and scientific funding programmes in both the European Union (EU) and USA. Precision medicine is a key component of both Horizon 2020 (the EU Framework Programme for Research and Innovation) and the White House's Precision Medicine Initiative. Precision medicine promises to revolutionize patient care and treatment decisions. However, the participants in precision medicine are faced with a considerable central challenge. Greater volumes of data from a wider variety of sources are being generated and analysed than ever before; yet, this heterogeneous information must be integrated and incorporated into personalized predictive models, the output of which must be intelligible to non-computationally trained clinicians. Drawing primarily from the field of 'oncology', this article will introduce key concepts and challenges of precision medicine and some of the approaches currently being implemented to overcome these challenges. Finally, this article also covers the criticisms of precision medicine overpromising on its potential to transform patient care.

biochemical research methods,mathematical & computational biology
Data Integration Challenges for Machine Learning in Precision Medicine

Mireya Martínez-García,Enrique Hernández-Lemus

DOI: https://doi.org/10.3389/fmed.2021.784455

IF: 3.9

2022-01-25

Frontiers in Medicine

Abstract:A main goal of Precision Medicine is that of incorporating and integrating the vast corpora on different databases about the molecular and environmental origins of disease, into analytic frameworks, allowing the development of individualized, context-dependent diagnostics, and therapeutic approaches. In this regard, artificial intelligence and machine learning approaches can be used to build analytical models of complex disease aimed at prediction of personalized health conditions and outcomes. Such models must handle the wide heterogeneity of individuals in both their genetic predisposition and their social and environmental determinants. Computational approaches to medicine need to be able to efficiently manage, visualize and integrate, large datasets combining structure, and unstructured formats. This needs to be done while constrained by different levels of confidentiality, ideally doing so within a unified analytical architecture. Efficient data integration and management is key to the successful application of computational intelligence approaches to medicine. A number of challenges arise in the design of successful designs to medical data analytics under currently demanding conditions of performance in personalized medicine, while also subject to time, computational power, and bioethical constraints. Here, we will review some of these constraints and discuss possible avenues to overcome current challenges.

medicine, general & internal
Challenges and Outlooks in Precision Medicine: Expectations Versus Reality

Rachel E Yan,Jeffrey P Greenfield

DOI: https://doi.org/10.1016/j.wneu.2024.06.142

Abstract:Recent developments in technology have led to rapid advances in precision medicine, especially due to the rise of next-generation sequencing and molecular profiling. These technological advances have led to rapid advances in research, including increased tumor subtype resolution, new therapeutic agents, and mechanistic insights. Certain therapies have even been approved for molecular biomarkers across histopathological diagnoses; however, translation of research findings to the clinic still faces a number of challenges. In this review, the authors discuss several key challenges to the clinical integration of precision medicine, including the blood-brain barrier, both a lack and excess of molecular targets, and tumor heterogeneity/escape from therapy. They also highlight a few key efforts to address these challenges, including new frontiers in drug delivery, a rapidly expanding treatment repertoire, and improvements in active response monitoring. With continued improvements and developments, the authors anticipate that precision medicine will increasingly become the gold standard for clinical care.
Developing predictive precision medicine models by exploiting real-world data using machine learning methods

Panagiotis C. Theocharopoulos,Sotiris Bersimis,Spiros V. Georgakopoulos,Antonis Karaminas,Sotiris K. Tasoulis,Vassilis P. Plagianakos

DOI: https://doi.org/10.1080/02664763.2024.2315451

IF: 1.416

2024-02-15

Journal of Applied Statistics

Abstract:Computational Medicine encompasses the application of Statistical Machine Learning and Artificial Intelligence methods on several traditional medical approaches, including biochemical testing which is extremely valuable both for early disease prognosis and long-term individual monitoring, as it can provide important information about a person's health status. However, using Statistical Machine Learning and Artificial Intelligence algorithms to analyze biochemical test data from Electronic Health Records requires several preparatory steps, such as data manipulation and standardization. This study presents a novel approach for utilizing Electronic Health Records from large, real-world databases to develop predictive precision medicine models by exploiting Artificial Intelligence. Furthermore, to demonstrate the effectiveness of this approach, we compare the performance of various traditional Statistical Machine Learning and Deep Learning algorithms in predicting individuals' future biochemical test outcomes. Specifically, using data from a large real-world database, we exploit a longitudinal format of the data in order to predict the future values of 15 biochemical tests and identify individuals at high risk. The proposed approach and the extensive model comparison contribute to the personalized approach that modern medicine aims to achieve.

statistics & probability
From hype to reality: data science enabling personalized medicine

Holger Fröhlich,Rudi Balling,Niko Beerenwinkel,Oliver Kohlbacher,Santosh Kumar,Thomas Lengauer,Marloes H Maathuis,Yves Moreau,Susan A Murphy,Teresa M Przytycka,Michael Rebhan,Hannes Röst,Andreas Schuppert,Matthias Schwab,Rainer Spang,Daniel Stekhoven,Jimeng Sun,Andreas Weber,Daniel Ziemek,Blaz Zupan

DOI: https://doi.org/10.1186/s12916-018-1122-7

2018-08-27

Abstract:Background: Personalized, precision, P4, or stratified medicine is understood as a medical approach in which patients are stratified based on their disease subtype, risk, prognosis, or treatment response using specialized diagnostic tests. The key idea is to base medical decisions on individual patient characteristics, including molecular and behavioral biomarkers, rather than on population averages. Personalized medicine is deeply connected to and dependent on data science, specifically machine learning (often named Artificial Intelligence in the mainstream media). While during recent years there has been a lot of enthusiasm about the potential of 'big data' and machine learning-based solutions, there exist only few examples that impact current clinical practice. The lack of impact on clinical practice can largely be attributed to insufficient performance of predictive models, difficulties to interpret complex model predictions, and lack of validation via prospective clinical trials that demonstrate a clear benefit compared to the standard of care. In this paper, we review the potential of state-of-the-art data science approaches for personalized medicine, discuss open challenges, and highlight directions that may help to overcome them in the future. Conclusions: There is a need for an interdisciplinary effort, including data scientists, physicians, patient advocates, regulatory agencies, and health insurance organizations. Partially unrealistic expectations and concerns about data science-based solutions need to be better managed. In parallel, computational methods must advance more to provide direct benefit to clinical practice.
Big data hurdles in precision medicine and precision public health

Mattia Prosperi,Jae S Min,Jiang Bian,François Modave

DOI: https://doi.org/10.1186/s12911-018-0719-2

2018-12-29

Abstract:Background: Nowadays, trendy research in biomedical sciences juxtaposes the term 'precision' to medicine and public health with companion words like big data, data science, and deep learning. Technological advancements permit the collection and merging of large heterogeneous datasets from different sources, from genome sequences to social media posts or from electronic health records to wearables. Additionally, complex algorithms supported by high-performance computing allow one to transform these large datasets into knowledge. Despite such progress, many barriers still exist against achieving precision medicine and precision public health interventions for the benefit of the individual and the population. Main body: The present work focuses on analyzing both the technical and societal hurdles related to the development of prediction models of health risks, diagnoses and outcomes from integrated biomedical databases. Methodological challenges that need to be addressed include improving semantics of study designs: medical record data are inherently biased, and even the most advanced deep learning's denoising autoencoders cannot overcome the bias if not handled a priori by design. Societal challenges to face include evaluation of ethically actionable risk factors at the individual and population level; for instance, usage of gender, race, or ethnicity as risk modifiers, not as biological variables, could be replaced by modifiable environmental proxies such as lifestyle and dietary habits, household income, or access to educational resources. Conclusions: Data science for precision medicine and public health warrants an informatics-oriented formalization of the study design and interoperability throughout all levels of the knowledge inference process, from the research semantics, to model development, and ultimately to implementation.
From Data Mining of Public Sources to Clinical Decision Support in Personalized Medicine

Valeriya Vishnevskaya,Stefan Sigle,Christian Fegeler

DOI: https://doi.org/10.3233/SHTI240734

2024-08-22

Abstract:Personalized medicine enables precise tumor treatment for a patient's molecular genetic profile. To devise optimal targeted treatment plans for patients in a molecular tumor board, physicians must consider alterations on gene- and proteins levels but also cancer cell phenotypes. Machine learning can uncover buried patterns, extract pivotal information, and unveil corresponding insights from available data. Publicly available datasets provide the amounts of data necessary. This work outlines the efficacy of various machine learning algorithms which could eventually serve as clinical decision support in a precision oncology setting. Leveraging algorithms including Random Forest, Decision tree, XGBoost, Logistic regression, Gaussian Naive Bayes, k nearest neighbor, and AdaBoost, we conducted two experiments for the breast invasive carcinoma dataset. Incorporated data includes patient-, molecular- and treatment data. The aim of the investigation was to predict medication treatment or type of treatment based on genetic profile. After preprocessing and application of ML algorithms, the first results were promising. Multiple factors challenge application in clinical care settings without carefully considering the limitations.
Are innovation and new technologies in precision medicine paving a new era in patients centric care?

Attila A. Seyhan,Claudio Carini

DOI: https://doi.org/10.1186/s12967-019-1864-9

IF: 8.44

2019-04-05

Journal of Translational Medicine

Abstract:Healthcare is undergoing a transformation, and it is imperative to leverage new technologies to generate new data and support the advent of precision medicine (PM). Recent scientific breakthroughs and technological advancements have improved our understanding of disease pathogenesis and changed the way we diagnose and treat disease leading to more precise, predictable and powerful health care that is customized for the individual patient. Genetic, genomics, and epigenetic alterations appear to be contributing to different diseases. Deep clinical phenotyping, combined with advanced molecular phenotypic profiling, enables the construction of causal network models in which a genomic region is proposed to influence the levels of transcripts, proteins, and metabolites. Phenotypic analysis bears great importance to elucidat the pathophysiology of networks at the molecular and cellular level. Digital biomarkers (BMs) can have several applications beyond clinical trials in diagnostics—to identify patients affected by a disease or to guide treatment. Digital BMs present a big opportunity to measure clinical endpoints in a remote, objective and unbiased manner. However, the use of "omics" technologies and large sample sizes have generated massive amounts of data sets, and their analyses have become a major bottleneck requiring sophisticated computational and statistical methods. With the wealth of information for different diseases and its link to intrinsic biology, the challenge is now to turn the multi-parametric taxonomic classification of a disease into better clinical decision-making by more precisely defining a disease. As a result, the big data revolution has provided an opportunity to apply artificial intelligence (AI) and machine learning algorithms to this vast data set. The advancements in digital health opportunities have also arisen numerous questions and concerns on the future of healthcare practices in particular with what regards the reliability of AI diagnostic tools, the impact on clinical practice and vulnerability of algorithms. AI, machine learning algorithms, computational biology, and digital BMs will offer an opportunity to translate new data into actionable information thus, allowing earlier diagnosis and precise treatment options. A better understanding and cohesiveness of the different components of the knowledge network is a must to fully exploit the potential of it.

medicine, research & experimental
Personalised Medicine: Establishing predictive machine learning models for drug responses in patient derived cell culture

Abbi Abdel-Rehim,Oghenejokpeme Orhobor,Gareth Griffiths,Larisa Soldatova,Ross D. King

2024-08-23

Abstract:The concept of personalised medicine in cancer therapy is becoming increasingly important. There already exist drugs administered specifically for patients with tumours presenting well-defined mutations. However, the field is still in its infancy, and personalised treatments are far from being standard of care. Personalised medicine is often associated with the utilisation of omics data. Yet, implementation of multi-omics data has proven difficult, due to the variety and scale of the information within the data, as well as the complexity behind the myriad of interactions taking place within the cell. An alternative approach to precision medicine is to employ a function-based profile of the cell. This involves screening a range of drugs against patient derived cells. Here we demonstrate a proof-of-concept, where a collection of drug screens against a highly diverse set of patient-derived cell lines, are leveraged to identify putative treatment options for a 'new patient'. We show that this methodology is highly efficient in ranking the drugs according to their activity towards the target cells. We argue that this approach offers great potential, as activities can be efficiently imputed from various subsets of the drug treated cell lines that do not necessarily originate from the same tissue type.

Biomolecules,Machine Learning
Reliable anti-cancer drug sensitivity prediction and prioritization

Kerstin Lenhof,Lea Eckhart,Lisa-Marie Rolli,Andrea Volkamer,Hans-Peter Lenhof

DOI: https://doi.org/10.1038/s41598-024-62956-6

IF: 4.6

2024-05-30

Scientific Reports

Abstract:The application of machine learning (ML) to solve real-world problems does not only bear great potential but also high risk. One fundamental challenge in risk mitigation is to ensure the reliability of the ML predictions, i.e., the model error should be minimized, and the prediction uncertainty should be estimated. Especially for medical applications, the importance of reliable predictions can not be understated. Here, we address this challenge for anti-cancer drug sensitivity prediction and prioritization. To this end, we present a novel drug sensitivity prediction and prioritization approach guaranteeing user-specified certainty levels. The developed conformal prediction approach is applicable to classification, regression, and simultaneous regression and classification. Additionally, we propose a novel drug sensitivity measure that is based on clinically relevant drug concentrations and enables a straightforward prioritization of drugs for a given cancer sample.

multidisciplinary sciences
Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis

Zeeshan Ahmed

DOI: https://doi.org/10.1186/s40246-020-00287-z

2020-10-02

Human Genomics

Abstract:Abstract Precision medicine aims to empower clinicians to predict the most appropriate course of action for patients with complex diseases like cancer, diabetes, cardiomyopathy, and COVID-19. With a progressive interpretation of the clinical, molecular, and genomic factors at play in diseases, more effective and personalized medical treatments are anticipated for many disorders. Understanding patient’s metabolomics and genetic make-up in conjunction with clinical data will significantly lead to determining predisposition, diagnostic, prognostic, and predictive biomarkers and paths ultimately providing optimal and personalized care for diverse, and targeted chronic and acute diseases. In clinical settings, we need to timely model clinical and multi-omics data to find statistical patterns across millions of features to identify underlying biologic pathways, modifiable risk factors, and actionable information that support early detection and prevention of complex disorders, and development of new therapies for better patient care. It is important to calculate quantitative phenotype measurements, evaluate variants in unique genes and interpret using ACMG guidelines, find frequency of pathogenic and likely pathogenic variants without disease indicators, and observe autosomal recessive carriers with a phenotype manifestation in metabolome. Next, ensuring security to reconcile noise, we need to build and train machine-learning prognostic models to meaningfully process multisource heterogeneous data to identify high-risk rare variants and make medically relevant predictions. The goal, today, is to facilitate implementation of mainstream precision medicine to improve the traditional symptom-driven practice of medicine, and allow earlier interventions using predictive diagnostics and tailoring better-personalized treatments. We strongly recommend automated implementation of cutting-edge technologies, utilizing machine learning (ML) and artificial intelligence (AI) approaches for the multimodal data aggregation, multifactor examination, development of knowledgebase of clinical predictors for decision support, and best strategies for dealing with relevant ethical issues.

genetics & heredity
Epistemology, Ethics, and Progress in Precision Medicine

Spencer Phillips Hey,Brianna Barsanti-Innes

DOI: https://doi.org/10.1353/pbm.2016.0026

Abstract:The emerging paradigm of precision medicine strives to leverage the tools of molecular biology to prospectively tailor treatments to the individual patient. Fundamental to the success of this movement is the discovery and validation of "predictive biomarkers," which are properties of a patient's biological specimens that can be assayed in advance of therapy to inform the treatment decision. Unfortunately, research into biomarkers and diagnostics for precision medicine has fallen well short of expectations. In this essay, we examine the portfolio of research activities into the excision repair cross complement group 1 (ERCC1) gene as a predictive biomarker for precision lung cancer therapy as a case study in elucidating the epistemological and ethical obstacles to developing new precision medicines.
Precision Medicine: Steps along the Road to Combat Human Cancer

Samuel F. Nassar,Khadir Raddassi,Baljit Ubhi,Joseph Doktorski,Ahmad Abulaban

DOI: https://doi.org/10.3390/cells9092056

IF: 6

2020-09-09

Cells

Abstract:The diagnosis and treatment of diseases such as cancer is becoming more accurate and specialized with the advent of precision medicine techniques, research and treatments. Reaching down to the cellular and even sub-cellular level, diagnostic tests can pinpoint specific, individual information from each patient, and guide providers to a more accurate plan of treatment. With this advanced knowledge, researchers and providers can better gauge the effectiveness of drugs, radiation, and other therapies, which is bound to lead to a more accurate, if not more positive, prognosis. As precision medicine becomes more established, new techniques, equipment, materials and testing methods will be required. Herein, we will examine the recent innovations in assays, devices and software, along with next generation sequencing in genomics diagnostics which are in use or are being developed for personalized medicine. So as to avoid duplication and produce the fullest possible benefit, all involved must be strongly encouraged to collaborate, across national borders, public and private sectors, science, medicine and academia alike. In this paper we will offer recommendations for tools, research and development, along with ideas for implementation. We plan to begin with discussion of the lessons learned to date, and the current research on pharmacogenomics. Given the steady stream of advances in imaging mass spectrometry and nanoLC-MS/MS, and use of genomic, proteomic and metabolomics biomarkers to distinguish healthy tissue from diseased cells, there is great potential to utilize pharmacogenomics to tailor a drug or drugs to a particular cohort of patients. Such efforts very well may bring increased hope for small groups of non-responders and those who have demonstrated adverse reactions to current treatments.

cell biology
Tribulations and future opportunities for artificial intelligence in precision medicine

Claudio Carini,Attila A Seyhan

DOI: https://doi.org/10.1186/s12967-024-05067-0

2024-04-30

Abstract:Upon a diagnosis, the clinical team faces two main questions: what treatment, and at what dose? Clinical trials' results provide the basis for guidance and support for official protocols that clinicians use to base their decisions. However, individuals do not consistently demonstrate the reported response from relevant clinical trials. The decision complexity increases with combination treatments where drugs administered together can interact with each other, which is often the case. Additionally, the individual's response to the treatment varies with the changes in their condition. In practice, the drug and the dose selection depend significantly on the medical protocol and the medical team's experience. As such, the results are inherently varied and often suboptimal. Big data and Artificial Intelligence (AI) approaches have emerged as excellent decision-making tools, but multiple challenges limit their application. AI is a rapidly evolving and dynamic field with the potential to revolutionize various aspects of human life. AI has become increasingly crucial in drug discovery and development. AI enhances decision-making across different disciplines, such as medicinal chemistry, molecular and cell biology, pharmacology, pathology, and clinical practice. In addition to these, AI contributes to patient population selection and stratification. The need for AI in healthcare is evident as it aids in enhancing data accuracy and ensuring the quality care necessary for effective patient treatment. AI is pivotal in improving success rates in clinical practice. The increasing significance of AI in drug discovery, development, and clinical trials is underscored by many scientific publications. Despite the numerous advantages of AI, such as enhancing and advancing Precision Medicine (PM) and remote patient monitoring, unlocking its full potential in healthcare requires addressing fundamental concerns. These concerns include data quality, the lack of well-annotated large datasets, data privacy and safety issues, biases in AI algorithms, legal and ethical challenges, and obstacles related to cost and implementation. Nevertheless, integrating AI in clinical medicine will improve diagnostic accuracy and treatment outcomes, contribute to more efficient healthcare delivery, reduce costs, and facilitate better patient experiences, making healthcare more sustainable. This article reviews AI applications in drug development and clinical practice, making healthcare more sustainable, and highlights concerns and limitations in applying AI.
Towards AI-Based Precision Oncology: A Machine Learning Framework for Personalized Counterfactual Treatment Suggestions based on Multi-Omics Data

Manuel Schürch,Laura Boos,Viola Heinzelmann-Schwarz,Gabriele Gut,Michael Krauthammer,Andreas Wicki,Tumor Profiler Consortium

2024-02-19

Abstract:AI-driven precision oncology has the transformative potential to reshape cancer treatment by leveraging the power of AI models to analyze the interaction between complex patient characteristics and their corresponding treatment outcomes. New technological platforms have facilitated the timely acquisition of multimodal data on tumor biology at an unprecedented resolution, such as single-cell multi-omics data, making this quality and quantity of data available for data-driven improved clinical decision-making. In this work, we propose a modular machine learning framework designed for personalized counterfactual cancer treatment suggestions based on an ensemble of machine learning experts trained on diverse multi-omics technologies. These specialized counterfactual experts per technology are consistently aggregated into a more powerful expert with superior performance and can provide both confidence and an explanation of its decision. The framework is tailored to address critical challenges inherent in data-driven cancer research, including the high-dimensional nature of the data, and the presence of treatment assignment bias in the retrospective observational data. The framework is showcased through comprehensive demonstrations using data from in-vitro and in-vivo treatment responses from a cohort of patients with ovarian cancer. Our method aims to empower clinicians with a reality-centric decision-support tool including probabilistic treatment suggestions with calibrated confidence and personalized explanations for tailoring treatment strategies to multi-omics characteristics of individual cancer patients.

Quantitative Methods,Machine Learning
Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer

Jenny Fitzgerald,Debra Higgins,Claudia Mazo Vargas,William Watson,Catherine Mooney,Arman Rahman,Niamh Aspell,Amy Connolly,Claudia Aura Gonzalez,William Gallagher

DOI: https://doi.org/10.1136/jclinpath-2020-207351

2021-06-11

Journal of Clinical Pathology

Abstract:Clinical workflows in oncology depend on predictive and prognostic biomarkers. However, the growing number of complex biomarkers contributes to costly and delayed decision-making in routine oncology care and treatment. As cancer is expected to rank as the leading cause of death and the single most important barrier to increasing life expectancy in the 21st century, there is a major emphasis on precision medicine, particularly individualisation of treatment through better prediction of patient outcome. Over the past few years, both surgical and pathology specialties have suffered cutbacks and a low uptake of pathology specialists means a solution is required to enable high-throughput screening and personalised treatment in this area to alleviate bottlenecks. Digital imaging in pathology has undergone an exponential period of growth. Deep-learning (DL) platforms for hematoxylin and eosin (H&E) image analysis, with preliminary artificial intelligence (AI)-based grading capabilities of specimens, can evaluate image characteristics which may not be visually apparent to a pathologist and offer new possibilities for better modelling of disease appearance and possibly improve the prediction of disease stage and patient outcome. Although digital pathology and AI are still emerging areas, they are the critical components for advancing personalised medicine. Integration of transcriptomic analysis, clinical information and AI-based image analysis is yet an uncultivated field by which healthcare professionals can make improved treatment decisions in cancer. This short review describes the potential application of integrative AI in offering better detection, quantification, classification, prognosis and prediction of breast and prostate cancer and also highlights the utilisation of machine learning systems in biomarker evaluation.

pathology

Practical challenges for precision medicine

Learning Personalized Treatment Decisions in Precision Medicine: Disentangling Treatment Assignment Bias in Counterfactual Outcome Prediction and Biomarker Identification

Artificial Intelligence, Physiological Genomics, and Precision Medicine.

Precision psychiatry: predicting predictability

Problems, challenges and promises: perspectives on precision medicine

Data Integration Challenges for Machine Learning in Precision Medicine

Challenges and Outlooks in Precision Medicine: Expectations Versus Reality

Developing predictive precision medicine models by exploiting real-world data using machine learning methods

From hype to reality: data science enabling personalized medicine

Big data hurdles in precision medicine and precision public health

From Data Mining of Public Sources to Clinical Decision Support in Personalized Medicine

Are innovation and new technologies in precision medicine paving a new era in patients centric care?

Personalised Medicine: Establishing predictive machine learning models for drug responses in patient derived cell culture

Reliable anti-cancer drug sensitivity prediction and prioritization

Practicing precision medicine with intelligently integrative clinical and multi-omics data analysis

Epistemology, Ethics, and Progress in Precision Medicine

Precision Medicine: Steps along the Road to Combat Human Cancer

Tribulations and future opportunities for artificial intelligence in precision medicine

Towards AI-Based Precision Oncology: A Machine Learning Framework for Personalized Counterfactual Treatment Suggestions based on Multi-Omics Data

Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer